论文部分内容阅读
目的比较恩替卡韦分散片与阿德福韦酯治疗失代偿期乙型肝炎肝硬化的临床疗效。方法选取失代偿期乙型肝炎肝硬化患者90例,随机分为研究组(n=45)和对照组(n=45),研究组给予恩替卡韦分散片治疗,对照组给予阿德福韦酯胶囊治疗,比较2组患者治疗前、治疗24周与48周后血清丙氨酸氨基转移酶(ALT)、总胆红素(TBIL)、乙肝病毒DNA(HBV-DNA)、乙肝病毒e抗原(HBe Ag)水平。结果 2组患者治疗前血清ALT、TBIL、HBVDNA、HBe Ag水平比较差异均无统计学意义(P>0.05);2组患者治疗24周、48周后血清ALT、TBIL、HBV-DNA、HBe Ag水平较治疗前均显著降低,差异均有统计学意义(P<0.05);且2组患者治疗48周后血清ALT、TBIL、HBVDNA、HBe Ag水平较治疗24周后显著降低,差异均有统计学意义(P<0.05)。研究组治疗24周后和48周后血清ALT、TBIL、HBV-DNA、HBe Ag水平均低于对照组,差异均有统计学意义(P<0.05)。结论恩替卡韦分散片治疗失代偿期乙型肝炎肝硬化临床疗效显著优于阿德福韦酯,患者肝功能恢复较好,值得临床进一步推广使用。
Objective To compare the clinical efficacy of entecavir dispersible tablets and adefovir dipivoxil in decompensated hepatitis B cirrhosis. Methods Ninety patients with decompensated hepatitis B cirrhosis were randomly divided into study group (n = 45) and control group (n = 45). The study group was treated with entecavir dispersible tablets and the control group received adefovir dipivoxil Capsule treatment. The levels of serum alanine aminotransferase (ALT), total bilirubin (TBIL), hepatitis B virus DNA (HBV-DNA) and hepatitis B virus e antigen HBe Ag) levels. Results The serum levels of ALT, TBIL, HBVDNA and HBe Ag in the two groups were not significantly different before treatment (P> 0.05). The levels of ALT, TBIL, HBV-DNA, HBe Ag (P <0.05). The levels of ALT, TBIL, HBVDNA and HBeAg in the two groups after 48 weeks of treatment were significantly lower than those of the control group after 24 weeks of treatment, with statistical differences Significance (P <0.05). The levels of serum ALT, TBIL, HBV-DNA and HBe Ag in the study group after 24 weeks and 48 weeks of treatment were both lower than those in the control group (P <0.05). Conclusion Entecavir dispersible tablets in the treatment of decompensated hepatitis B cirrhosis clinical efficacy was significantly better than adefovir dipivoxil, liver function recovery is good, it is worth further clinical use.